Approximately 1% of Canadians are affected by schizophrenia, a treatable yet complex mental illness that affects how a person thinks, feels, behaves and relates to others. It is believed to be caused by a combination of biological and environmental factors that contribute to its development.2
Schizophrenia includes “positive” and “negative” symptoms of psychosis, as well as cognitive symptoms.3
At Johnson & Johnson Innovative Medicine, we’ve led the way in developing treatments to allow patients to live well with schizophrenia.
Innovation is at our core as we work on finding new ways to reduce the burden of disease for those affected by mental illness.
Johnson & Johnson Innovative Medicine’s researchers are exploring the emerging science in neurodegenerative and neuroinflammatory disorders, including synaptic plasticity and cellular resilience. We’re also seeking to use breakthrough technologies in imaging, genomics and associated biomarkers.